Items where authors include "Ukropec, J"

Export as [feed] Atom [feed] RSS
Number of items: 6.


San-Miguel, JF, Avet-Loiseau, H, Paiva, B et al. (24 more authors) (2022) Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood, 139 (4). pp. 492-501. ISSN 0006-4971

Cook, G, Corso, A, Streetly, M et al. (11 more authors) (2021) Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy, 9. pp. 139-151. ISSN 2366-1070

Kaufman, JL, Dimopoulos, MA, White, D et al. (26 more authors) (2020) Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 10 (11). 111. ISSN 2044-5385

Bahlis, NJ, Dimopoulos, MA, White, DJ et al. (16 more authors) (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 34. pp. 1875-1884. ISSN 0887-6924

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Conference or Workshop Item

Kaufman, JL, Usmani, SZ, San-Miguel, J et al. (16 more authors) (2020) Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: 61st American Society of Hematology (ASH) Annual Meeting, 07-10 Dec 2019, Orlando, Florida, USA.

This list was generated on Sun Feb 25 22:23:32 2024 GMT.